SaraLouiseZaknoenMD

PubMed

• 26 citations
  Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in ...
  Martin J. Edelman, Ming Tan, Mary J. Fidler, Rachel E. Sanborn, Greg Otterson, Lecia V. Sequist, Tracey L. Evans, Bryan J. Schneider, Roger Keresztes, John S. Rogers, ...> ;Journal of Clinical Oncology. 2015 Jan 10
• 42 citations
  Therapeutic potential of ERK5 targeting in triple negative breast cancer
  María Jesús Ortiz-Ruiz, Stela Álvarez-Fernández, Tracy Parrott, Sara Zaknoen, Francis Burrows, Alberto Ocaña, Atanasio Pandiella, Azucena Esparís-Ogando> ;Oncotarget. 2014 Aug 11
• 26 citations
  A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lu...
  Barbara J. Gitlitz, Eric Bernstein, Edgardo S. Santos, Greg Otterson, Ginger L. Milne, Mary Syto, Francis Burrows, Sara Zaknoen> ;Journal of Thoracic Oncology. 2014 Apr 1
• 40 citations
  Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
  Stela Álvarez-Fernández, María Jesús Ortiz-Ruiz, Tracy Parrott, Sara Zaknoen, Enrique M. Ocio, Jesús F. San Miguel, Francis Burrows, Azucena Esparís-Ogando, Atanasio P...> ;Clinical Cancer Research. 2013 May 15
• 43 citations
  Apricoxib, a novel inhibitor of COX-2 markedly improves standard therapy response in molecularly defined models of pancreatic cancer
  Amanda Kirane, Jason E. Toombs, Katherine T. Ostapoff, Juliet G. Carbon, Sara Zaknoen, Jordan Braunfeld, Roderich E. Schwarz, Francis Burrows, Rolf A. Brekken> ;Clinical Cancer Research. 2012 Sep 15
• 21 citations
  Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.
  Amanda Kirane, Jason E. Toombs, Jill E. Larsen, Katherine T. Ostapoff, Katheryn R Meshaw, Sara Zaknoen, Rolf A. Brekken, Francis Burrows> ;Carcinogenesis. 2012 Sep 1
• 5 citations
  Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.
  M. St. John, Gerald Wang, Jie Luo, Mariam Dohadwala, D Hu, Yuan Lin, Miranda Dennis, Jay M. Lee, David Elashoff, T Lawhon, Sara Zaknoen, Francis Burrows, Steven M. Dub...> ;British Journal of Cancer. 2012 Aug 7
• Apricot-P: A randomized placebo-controlled phase II study of COX-2 inhibitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastat...
  Modiano M, Keogh GP, Manges R, Stella PJ, Milne G, Looper E, Zaknoen SL> ;J. Clin. Oncol.. 2012-02-01
• Apricot-l: Results of a biomarker-based phase II randomized placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) p...
  Gitlitz BJ, Bernstein ED, Keogh GP, Santos ES, Otterson GA, Milne G, Syto M, Zaknoen SL> ;J. Clin. Oncol.. 2011-05-20
• 15 citations
  Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
  Karen L. Reckamp, Barbara J. Gitlitz, Lin-Chi Chen, Ravi Patel, Ginger L. Milne, Mary Syto, Deborah Jezior, Sara Zaknoen> ;Cancer. 2011 Feb 15
• TG01, a new potent COX-2 inhibitor in combination with erlotinib in metastatic or recurrent non-small cell lung cancer (NSCLC) patients: A phase 1 study.
  Reckamp KL, Patel R, Chen L, Gitlitz BJ, Davies AM, Jezior D, Zaknoen S> ;J. Clin. Oncol.. 2008-05-20
• 28 citations
  A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
  Martin Forster, Stan B. Kaye, Amit M. Oza, I. Sklenar, A. Johri, Wing Cheung, Sara Zaknoen, Martin Gore> ;Clinical Cancer Research. 2007 Jul 15
• 80 citations
  Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
  Edward S. Kim, Merrill S. Kies, Frank V. Fossella, Bonnie S. Glisson, Sara Zaknoen, Paul Statkevich, Reginald F. Munden, Carmen Summey, Katherine M.W. Pisters, Vali M....> ;Cancer. 2005 Aug 1
• Phase I trial of patupilone plus carboplatin in patients with advanced cancer.
  Gore M, Kaye S, Oza A, Keyzor C, Pyle L, Pereno R, Sklenar I, Zaknoen S, Johri A> ;J. Clin. Oncol.. 2005-06-01
• Phase I dose optimization trial of patupilone in previously treated patients (pts) with advanced colon cancer (ACC).
  Melichar B, Tabernero J, Casado E, Bridgewater J, Hamm J, Sklenar I, Holland J, Cheung W, Zaknoen S, Johri A> ;J. Clin. Oncol.. 2005-06-01
• 25 citations
  Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas
  E. S. Newlands, T Foster, S Zaknoen> ;British Journal of Cancer. 2003 Jul 21
• 187 citations
  Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
  Jennifer A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James M. Provenzale, Roger E. McLendon, Sridharan Gururangan, Darell D. Bigner...> ;Journal of Clinical Oncology. 2003 Feb 15
• 86 citations
  A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy
  Mark R. Gilbert, Henry S. Friedman, John F. Kuttesch, Michael D. Prados, Jeffrey J. Olson, Gregory H. Reaman, Sara L. Zaknoen> ;Neuro-Oncology. 2002 Oct 1
• 64 citations
  Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
  Sridharan Gururangan, Ilkcan Cokgor, Jeremy N. Rich, Shari Edwards, Mary Lou Affronti, Jennifer A. Quinn, James E. Herndon, James M. Provenzale, Roger E. McLendon, San...> ;Neuro-Oncology. 2001 Oct 1
• 751 citations
  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
  W. K. A. Yung, Robert E. Albright, Jeffrey J. Olson, R Fredericks, Karen Fink, Michael D. Prados, Michael Brada, Alexander M. Spence, Raymond J. Hohl, William R. Shapi...> ;British Journal of Cancer. 2000 Sep 1
• 577 citations
  Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
  W. K. Alfred Yung, M. Prados, Ricardo Yaya-Tur, Steven S. Rosenfeld, Michael Brada, Henry S. Friedman, Robert Albright, Jeffrey Olson, Susan M. Chang, Alison M. O'Neil...> ;Journal of Clinical Oncology. 1999 Sep 1
• 31 citations
  Infectious complications and immunodeficiency in patients with human T‐cell lymphotropic virus I‐associated adult T‐cell leukemia/lymphoma
  Jeffrey D. White, Sara Zaknoen, Claude Kasten-Sportes, Lois E. Top, Lydia Navarro-Román, David L. Nelson, Thomas A. Waldmann> ;Cancer. 1995 Apr 1
• 25 citations
  T-cell receptor gene rearrangement in T-cell large granular leukocyte leukemia: preferential V alpha but diverse J alpha usage in one of five patients
  Claude Kasten-Sportes, Sara Zaknoen, Ronald G. Steis, Wing C. Chan, Elliott F. Winton, Thomas A. Waldmann> ;Blood. 1994 Feb 1
• 167 citations
  The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia
  T. A. Waldmann, Jeffrey D. White, Carolyn K. Goldman, Lois E. Top, Angus Grant, Richard N. Bamford, Erich Roessler, Ivan D. Horak, Sara Zaknoen, Claude Kasten-Sportes> ;Blood. 1993 Sep 15
• 5 citations
  The Interleukin‐2 Receptor: A Target for Immunotherapy
  Thomas A. Waldmann, Carolyn K. Goldman, Lois E. Top, Angus Grant, Jack D. Burton, Richard N. Bamford, Erich Roessler, Ivan Horak, Sara Zaknoen, Claude Kasten-Sportes, ...> ;Annals of the New York Academy of Sciences. 1993 Jun 1
• Join now to see all